MedPath

Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation

Not Applicable
Recruiting
Conditions
Obstructive Sleep Apnea
Premature Ventricular Contraction (PVC)
Atrial Fibrillation (AF)
Premature Atrial Contraction
Registration Number
NCT07220525
Lead Sponsor
University of California, San Francisco
Brief Summary

Whereas the available evidence mostly supports chronic sleep disruption as a risk factor for incident AF, less is known about the near-term risk of a discrete atrial fibrillation (AF) episode following a night of disrupted or poor-quality sleep. This prospective, randomized, case-crossover study aims to examine the acute effects of sleep disruption on clinically relevant cardiac ectopy pertinent to AF.

Detailed Description

One hundred patients aged 21 years or older who have a hypoglossal nerve stimulation (HGNS) device implanted for obstructive sleep apnea, without a history of permanent AF, not on Class 1 or 3 antiarrhythmic medications and willing to participate in the study, will be randomized to "off-on" versus "on-off" periods (where "off" is turning off the HGNS device for one night and "on" is turning on the HGNS device), assuring no more than two consecutive days of either device use or not, over the ensuing 14 days. Participants will be fitted with an automatically recording electrocardiographic monitor. The primary endpoint will be the daily number of cardiac ectopic beats, and secondary endpoints: daily number of PACs, daily number of PVCs, and daily presence versus absence of AF episodes ≥ 30 seconds. Our primary analyses will employ intention-to-treat principles, examining randomization assignment as the primary predictor.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Are age 21 years or older
  • Have a HGNS device implanted for obstructive sleep apnea and followed up at UCSF Health
  • Are willing to abstain from using the upper airway stimulation device for no more than two consecutive days as instructed over the 14-day trial period
  • Able and willing to provide written informed consent
Exclusion Criteria
  • Currently pregnant or trying to get pregnant
  • Are currently taking class 1 or 3 anti-arrhythmic medications
  • Have a history of permanent AF or expected to have continuous AF throughout the study period
  • Have congenital heart disease
  • Ventricular pacing >40%
  • Are unable to read or sign to provide informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Ectopic beats24-hour time period

Daily number of ectopic beats as recorded with the adhesive heart monitor

Secondary Outcome Measures
NameTimeMethod
Premature Atrial Contractions (PACs)24-hour time period

Daily number of PACs as recorded with the adhesive heart monitor

Premature Ventricular Contractions (PVCs)24-hour time period

Daily number of PVCs as recorded with the adhesive heart monitor

Atrial Fibrillation (AF)24-hour time period

Daily presence of AF ≥30 seconds as recorded with the adhesive heart monitor

Trial Locations

Locations (1)

UCSF Medical Center at Parnassus

🇺🇸

San Francisco, California, United States

UCSF Medical Center at Parnassus
🇺🇸San Francisco, California, United States
Gregory Marcus, MD, MAS
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.